Filtered By:
Source: Circulation: Cardiovascular Quality and Outcomes
Condition: Bleeding
Drug: Warfarin

This page shows you your search results in order of date. This is page number 3.

Order by Relevance | Date

Total 33 results found since Jan 2013.

Abstract 303: Adoption of the Novel Oral Anticoagulant Dabigatran in Patients with Atrial Fibrillation Receiving Warfarin in Community Practice: Findings from ORBIT AF Poster Session III
Conclusions: Patients receiving warfarin who were switched to dabigatran were younger, with lower CHADS2 scores, better kidney function, and less concomitant cardiovascular disease than those not switched. This conservative transition pattern suggests greater physician emphasis on bleeding avoidance than on stroke risk reduction.
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2013 Category: Cardiology Authors: Holmes, D. N., Steinberg, B. A., Piccini, J. P., Ansell, J., Chang, P., Fonarow, G. C., Gersh, B., Mahaffey, K., Kowey, P., Thomas, L., Peterson, E. D., Hylek, E. Tags: Poster Session III Source Type: research

Abstract 234: Prior Warfarin Treatment and Intracranial Hemorrhage among Patients With Acute Ischemic Stroke Treated With Intravenous Tissue Plasminogen Activator: A Meta-analysis Poster Session II
Conclusions: These data suggested that the risk of sICH after thrombolytic therapy is not increased in patients using warfarin with sub therapeutic INR levels.
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2013 Category: Cardiology Authors: Li, H., Xian, Y., Laskowitz, D., Peterson, E. Tags: Poster Session II Source Type: research

Abstract 245: Indirect Comparison of Efficacy and Safety data in Atrial Fibrillation patients treated with Apixaban (Aristotle study) versus Dabigatran (Rely study) based on Chads2 Score Stratification Poster Session II
CONCLUSIONS: This analysis of the published data suggests similar efficacy for both agents when used in AF patients across the Chad2 score categories, however there was a trend for a higher major bleeding risks ( Chads 2 score 0-1 and 2 ) and a statistically significantly higher bleeding event rate (Chads2 score >=3) with DAB.
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2013 Category: Cardiology Authors: Rasty, S., Taheri, R. Tags: Poster Session II Source Type: research